本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 石家庄以岭药业股份有限公司（以下简称"公司"）定于 2023 年 5 月 18 日 下午 15：00-17：00 在全景网举办 2022 年度网上业绩说明会，本次年度业绩说 明会将采用网络远程的方式举行，投资者可登陆全景网"投资者关系互动平台" （http://ir.p5w.net）参与本次年度业绩说明会。 出席本次业绩说明会的人员有：董事长兼总经理吴相君先生、财务负责人李 晨光先生、董事会秘书吴瑞女士、独立董事韩志国先生。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 5 月 17 日 12：00 前访问 https://ir.p5w.net/zj/，或扫描下方二维码，进入问题征集 专题页面。公司将在 2022 年度业绩说明会上，对投资者普遍关注的问题进行回 答。 欢迎广大投资者积极参与。 特此公告。 证券代码：002603 证券简称：以岭药业 公告编号：2023-034 石家庄以岭药业股份有限公司 关于举 ...

Group 1: Financial Performance - The company's gross profit margin decreased due to rising raw material prices and a shift in product revenue composition, with lower-margin products gaining a higher revenue share [2][3]. - Cardiovascular products saw over 40% growth in the first half of 2014, with significant potential for further market expansion [3][5]. - Sales of Lianhua Qingwen capsules are supported by clinical efficacy and national policy, leading to an increasing market share [4]. Group 2: International Business Strategy - The international pharmaceutical business is currently focused on OEM operations, transitioning towards generic drug registrations and innovative traditional Chinese medicine sales abroad [3]. - The company anticipates a good order situation this year as it moves from the first to the second phase of its international strategy [3]. Group 3: Sales and Marketing - The sales team for patented traditional Chinese medicine is structured into several departments, covering over 90% of county-level markets in China [5]. - The company is managing sales expenses strategically, focusing on mature products while continuing to invest in new product market development [4]. Group 4: E-commerce Development - The company's e-commerce platform, Yiling Health City, launched on August 28, 2014, is performing well, with plans to expand product offerings and improve user experience [6]. - The platform aims to promote traditional Chinese medicine health concepts and provide educational resources [6].